Gilead Q2 FY26 loss per share widens to $(8.45); revenue rises 10% to $7.8 billionPUBT·Aug 4 at 03:09 PMGILD-2.14%ACLX0.00%
Arcellx's (ACLX) "Neutral" Rating Reiterated at Cantor FitzgeraldMarket Beat·Apr 29 at 10:34 AMACLX0.00%
Arcellx (NASDAQ:ACLX) Upgraded to Strong-Buy at Truist FinancialMarket Beat·Apr 28 at 05:02 AMACLX0.00%
Gilead Sciences Completes Acquisition of Arcellx Ahead of Potential Commercial Launch of Anito-cel | ACLX Stock NewsStockTitan·Apr 27 at 11:45 PMACLX0.00%GIS
Gilead Receives All Required Regulatory Approvals for the Acquisition of Arcellx and Extends Tender Offer | GILD Stock NewsStockTitan·Apr 16 at 11:30 PMACLX0.00%XBI-3.48%
Gilead’s Deal Spree Shifts Pipeline Toward Oncology And Potential UpsideSimplywall·Apr 10 at 01:02 AMACLX0.00%PBE-2.25%
Gilead Sciences Details Tubulis, Ouro, Arcellx Deals as Pipeline Catalyst, 2026 Updates LoomMarket Beat·Apr 7 at 06:08 PMPBE-2.25%VHT-0.61%
Gilead Acquisition Spree Continues With $3 Billion Tubulis Dealbenzinga_article·Apr 7 at 11:06 AMIHE-0.74%FBT-2.54%
